ARCHIVES

Trial In Metastatic Disease To Be Unblinded After Regorafenib Meets Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 34 No. 11 | November 25, 2011

Download PDF Visit The Full Archive

Related Articles

Wittes, Fraumeni Appointed As Division Directors

February 9, 1996

B.J. Kennedy, “Father of Medical Oncology,” Dead At 81

April 18, 2003

Phase III Trial of ThermoDox Fails to Meet Primary Endpoint

February 22, 2013

NCI sponsors Year-Round Shannon Awards Program

April 4, 1996

In Brief: Hew Approves Patent Request From U. Arizona; Califano Still Pondering Bioassay Program Fate

September 1, 1978

Bush Nominates von Eschenbach For FDA; Democrats Put Hold On Confirmation. von Eschenbach To Step Down As NCI Director, But Details Unavailable; No Acting Director Named. Applause, Outrage, Over Nomination. Now, von Eschenbach Leads A Retreat From 2015 Target Date For His Challenge Goal.

March 17, 2006